核心观点公司核心产品SKB264 用于EGFR突变3L NSCLC适应症国内顺利获批,这是继24 年底TNBC 获批后国内上市的第二个适应症,也是全球首个用于肺癌适应症的Trop-2 ADC 新药。此外,24 年10 月31 日SKB264 用于EGFR-TKI 耐药2L NSCLC 适应症NDA 获受理,同样有望于25 年顺利获批。合作伙伴默沙东积极布局SKB264 全球临床试验,目前已布局12...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.